| Application no. and date | 07811049.1 (espacenet) (Federated) (European Patent Register), 20070802 | | Patent/reg. no. and date | DK/EP 2049109, 20151118 | | Publication date | 20090422 | | Priority no. and date | US 835239 P, 20060802, US 873760 P, 20061208 | | EP pub. no. and date |
EP 2049109 20090422 | | Effective date | | | Applicant/owner | Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080, US | | Applicant ref. no. | P81505000DK00E | | Inventor | ADELMAN, Daniel, C., 23 Woodleaf Avenue
Redwood City, CA 94061, US,
SILVERMAN, Jeffrey, A., 1416 Columbus Avenue
Burlingame, CA 94010, US,
MICHELSON, Glenn, 98 Midcrest Way
San Francisco, CA 94131, US,
SCATENA, Caroline Darne, 58 Britt Court
Alameda, CA 94502, US | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 31/4375 (2006.01) , A61K 31/513 (2006.01) , A61K 31/7068 (2006.01) | | Title | Kombineret anvendelse af (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methyl¬amino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridin-3-carboxylsyre og cytarabin (Ara-C) til behandling af leukæmi | | Int. application no. | US2007017344 | | Int. publication no. | WO2008016702 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
